A single molecule inhibitor targeting both HDAC activity and PI3K signaling has recently been developed, which induced greater tumor growth inhibition and pro-apoptotic activity than single-target PI3K or HDAC inhibitors in vitro and in vivo [18]. The gene discussed is HDAC9; the disease is neoplasm.